The European Medicines Agency (EMA) has published revised Good Manufacturing Practice (GMP) guidelines specifically tailored for Advanced Therapy Medicinal Products (ATMPs), including gene therapies, CAR-T cell therapies, and tissue-engineered products.
Key Changes
- New requirements for donor screening traceability documentation
- Updated environmental monitoring standards for open-process manufacturing
- Clarified expectations for computerized systems validation in ATMP release testing